<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495844</url>
  </required_header>
  <id_info>
    <org_study_id>EP0069</org_study_id>
    <secondary_id>2014-003330-12</secondary_id>
    <nct_id>NCT02495844</nct_id>
  </id_info>
  <brief_title>A Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy</brief_title>
  <official_title>Double-blind, Randomized, Placebo-controlled Study of the Efficacy, Safety/Tolerability, and Pharmacokinetic Profile of UCB0942 in Adults With Highly Drug-resistant Focal Epilepsy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PRA Health Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess the efficacy, safety, and tolerability of the investigational drug
      UCB0942in adult subjects with drug-resistant focal epilepsy across multiple centers in
      Europe.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include a Screening Visit, a Prospective Outpatient Baseline Period (2 to 3
      weeks), an Inpatient Period (3 weeks), an Outpatient Period (8 weeks of treatment and 2 weeks
      of taper), and a Safety Follow-Up Period (4 weeks). The total study duration after screening
      will be 19 to 20 weeks. Approximately 6 months after the last visit subjects will be asked to
      return for an additional visit.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">February 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>75 % Responder Rate During the 2-week Inpatient Period</measure>
    <time_frame>During the 2-week Inpatient Period</time_frame>
    <description>The 75% responder rate is defined as the percentage of subjects with a 75 % or greater reduction in focal seizure frequency during the 2-week Inpatient Period compared with the Baseline Period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change in Weekly Focal Seizure Frequency During the 2-week Inpatient Period</measure>
    <time_frame>During the 2-week Inpatient Period</time_frame>
    <description>A negative value in median percent change reflects a reduction from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change in Weekly Focal Seizure Frequency During the Outpatient Maintenance Period</measure>
    <time_frame>During the Outpatient Maintenance Period (8 weeks)</time_frame>
    <description>A negative value in median percent change reflects a reduction from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Percent Change in Weekly Focal Seizure Frequency During the On-UCB0942 Overall Period</measure>
    <time_frame>During the On-UCB0942 Overall Period (approximately 11 weeks)</time_frame>
    <description>A negative value in median percent change reflects a reduction from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure-free Rate (All Seizures) During the 2-week Inpatient Period</measure>
    <time_frame>During the 2-week Inpatient Period</time_frame>
    <description>Seizure-free rate is reported as the percentage of seizure-free participants during the 2-week Inpatient Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure-free Rate (All Seizures) During the Last 4 Weeks of the Outpatient Maintenance Period</measure>
    <time_frame>During the last 4 weeks of the Outpatient Maintenance Period</time_frame>
    <description>Seizure-free rate is reported as the percentage of seizure-free participants during the last 4 weeks of the Outpatient Maintenance Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure-free Rate (All Seizures) During the On-UCB0942 Overall Period</measure>
    <time_frame>During the On-UCB0942 Overall Period (approximately 11 weeks)</time_frame>
    <description>Seizure-free rate is reported as the percentage of seizure-free participants during the On-UCB0942 Overall Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>75 % Responder Rate During the Last 4 Weeks of the Outpatient Maintenance Period</measure>
    <time_frame>During the last 4 weeks of the Outpatient Maintenance Period</time_frame>
    <description>The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>75 % Responder Rate During the On-UCB0942 Overall Period</measure>
    <time_frame>During the On-UCB0942 Overall Period (approximately 11 weeks)</time_frame>
    <description>The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Seizure Free Days (All Seizures) During the 2-week Inpatient Period</measure>
    <time_frame>During the 2-week Inpatient Period</time_frame>
    <description>For the active group, the 2-week Inpatient Period refers to the last 2 weeks of the Inpatient Period, while for the Placebo group, it refers to the first 2 weeks of the Inpatient Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Seizure-free Days (All Seizures) During the Outpatient Maintenance Period</measure>
    <time_frame>During the Outpatient Maintenance Period (8 weeks)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study</measure>
    <time_frame>All study duration (approximately 19 to 20 weeks)</time_frame>
    <description>Number of subjects experiencing at least one serious adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subject Withdrawals Due to Adverse Events (AEs) During the Course of the Study</measure>
    <time_frame>All study duration (approximately 19 to 20 weeks)</time_frame>
    <description>Number of subjects who withdrew from the study due adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Highly Drug-resistant Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>UCB0942</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>UCB0942/UCB0942</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo/UCB0942 (after 2-week inpatient period, placebo subjects will receive the experimental medicine, UCB0942).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB0942</intervention_name>
    <description>Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use</description>
    <arm_group_label>UCB0942</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UCB0942</intervention_name>
    <description>Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>UCB0942</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form: Film-coated tablet Route of administration: Oral use</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is an adult (18 years of age or more)

          -  Subject is able to understand the study and the ICF as assessed by the Investigator.
             Subjects with known mental retardation (defined as IQ below 70) are not eligible to
             participate. Subject and/or caregiver is considered reliable and capable of adhering
             to the protocol (eg, able to understand and complete diaries), visit schedule, and the
             medication intake scheme as instructed according to the judgment of the Investigator

          -  Subject fulfills ILAE (1989) criteria for focal epilepsy; clinical semiology should be
             described and fulfill criteria for focal seizures; there will have been an
             electroencephalogram (EEG) reading compatible with focal epilepsy in the last 5 years;
             the subject has no seizures that are not focal by the new ILAE criteria; a brain MRI
             (magnetic resonance imaging) or head CT (computed tomography) to be performed before
             randomization, if no such scan was performed in the last 5 years, and a report is
             available. If a scan was performed within the last 5 years but the epilepsy has not
             been stable since the last scan, a new scan should be obtained

          -  Subject has failed to achieve seizure control with ≥4 appropriately chosen
             Antiepileptic Drug (AED) regimens of adequate dose and duration, including the current
             treatment, as documented in medical records and per Investigator assessment of patient
             report

          -  Subject is currently treated with a stable dose of at least 1 AED for the 4 weeks
             prior to the Screening Visit (Visit 1) and throughout the duration of the Treatment
             Period with or without additional concurrent vagus nerve stimulation (VNS) or other
             neurostimulation treatments. The VNS must have been in place for at least 12 months
             with constant settings for at least 3 months and the battery life of unit anticipated
             to extend for the duration of study prior to the Screening Visit and throughout the
             duration of the study

          -  During the 4 weeks prior to Screening (Historical Baseline Period), subject must
             report to have had an average of at least 4 spontaneous and observable focal seizures
             per week (&quot;focal seizures&quot; refers to partial-onset seizures of type IA1, IB, and IC,
             but does not include type IA2, IA3, or IA4 seizures), and cannot have had any
             seizure-free period longer than 3 days (based on Investigator assessment of subject
             report and seizure diaries if available). The cut-off seizure frequency (4 seizures
             per week) and maximum seizure-free interval (3 days) must be maintained during the
             2-week Prospective Outpatient Baseline Period

          -  Female subjects of nonchildbearing potential (premenarcheal, postmenopausal for at
             least 2 years, bilateral oophorectomy or tubal ligation, and complete hysterectomy)
             are eligible. Female subjects of childbearing potential are eligible if they use
             medically accepted contraceptive methods. Oral or depot contraceptive treatment with
             at least ethinylestradiol 30 μg per intake used with an additional barrier
             contraception method, monogamous relationship with vasectomized or female partner, or
             double-barrier contraception are acceptable methods. The subject must understand the
             consequences and potential risks of inadequately protected sexual activity, be
             educated about and understand the proper use of contraceptive methods, and undertake
             to inform the Investigator of any potential change in status. Abstinence will be
             considered as an acceptable method of contraception if the Investigator can document
             that the subject agrees to be compliant when it is in line with the preferred and
             usual lifestyle of the subject

          -  Male subjects confirm that during the study period and for a period of 3 months after
             the final dose, when having sexual intercourse with a woman of childbearing potential,
             he will use a barrier contraceptive (eg, condom) and that the respective partner will
             use an additional contraceptive method

        Exclusion Criteria:

          -  Subject has participated in another study of an investigational medication (or medical
             device) within the last 30 days or is currently participating in another study of an
             investigational medication (or a medical device)

          -  Subject has a known hypersensitivity to any components of UCB0942 formulation or to
             similar drugs (LEV, BRV, or benzodiazepines), or a history of drug or other allergy
             that, in the opinion of the Investigator or UCB Study Physician, contraindicates
             her/his participation

          -  Subject has a current or past psychiatric condition that, in the opinion of the
             Investigator, could compromise his/her safety or ability to participate in this study
             including a history of schizophrenia, schizoaffective disorder, bipolar disorder, or
             severe unipolar depression. The presence of potential psychiatric exclusion criteria
             will be determined based on screening with the BPRS plus the Mini International
             Neuropsychiatric Interview (MINI)

          -  Subject has taken other (non-AED) prescription, nonprescription, dietary (eg,
             grapefruit or passion fruit), or herbal products that are potent inducers or
             inhibitors of the CYP3A4 pathway for 2 weeks (or 5 half-lives, whichever is longer)
             prior to the Baseline Visit

          -  Subject is currently treated with carbamazepine, phenytoin, primidone, or
             phenobarbital or any other drug known to induce CYP3A4 liver enzymes; Subject is
             taking tiagabine, felbamate, or vigabatrin; Subject is taking benzodiazepines,
             zolpidem, zaleplon, or zopiclone &gt;3 times per week for any indication

          -  Subject has a clinically significant abnormality on echocardiography at Screening or a
             history of rheumatic heart disease or other known valvular abnormalities

          -  Subjects with a history of hypersensitivity reactions or autoimmune disease

          -  Female subject who is pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Cares</last_name>
    <role>Study Director</role>
    <affiliation>+1 844 599 2273 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ep0069 103</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 101</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 102</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 201</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 402</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 408</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 401</name>
      <address>
        <city>Kehlkork</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 407</name>
      <address>
        <city>Marburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 403</name>
      <address>
        <city>Radeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 405</name>
      <address>
        <city>Ravensburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 601</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 602</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 302</name>
      <address>
        <city>Heeze</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 502</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 505</name>
      <address>
        <city>Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 506</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 501</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ep0069 503</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 29, 2015</study_first_submitted>
  <study_first_submitted_qc>July 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <results_first_submitted>July 18, 2018</results_first_submitted>
  <results_first_submitted_qc>February 4, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 5, 2019</results_first_posted>
  <last_update_submitted>February 4, 2019</last_update_submitted>
  <last_update_submitted_qc>February 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>UCB0942</keyword>
  <keyword>Treatment-resistant focal epilepsy</keyword>
  <keyword>Partial seizures</keyword>
  <keyword>Seizure therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02495844/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/44/NCT02495844/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment started in August 2015 and concluded in July 2017.</recruitment_details>
      <pre_assignment_details>Participant Flow refers to the Randomized Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo/UCB0942</title>
          <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
        </group>
        <group group_id="P2">
          <title>UCB0942/UCB0942</title>
          <description>Subjects received UCB0942.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE, non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Hepatitis Positivity</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Safety Set consisting of all subjects in the Randomized Set who received at least 1 dose of Investigational Medicinal Product (IMP).</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo/UCB0942</title>
          <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
        </group>
        <group group_id="B2">
          <title>UCB0942/UCB0942</title>
          <description>Subjects received UCB0942.</description>
        </group>
        <group group_id="B3">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="55"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.2" spread="8.7"/>
                    <measurement group_id="B2" value="36.2" spread="11.4"/>
                    <measurement group_id="B3" value="35.7" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI (kg/m^2)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.66" spread="4.82"/>
                    <measurement group_id="B2" value="27.20" spread="4.32"/>
                    <measurement group_id="B3" value="26.45" spread="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>75 % Responder Rate During the 2-week Inpatient Period</title>
        <description>The 75% responder rate is defined as the percentage of subjects with a 75 % or greater reduction in focal seizure frequency during the 2-week Inpatient Period compared with the Baseline Period.</description>
        <time_frame>During the 2-week Inpatient Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>75 % Responder Rate During the 2-week Inpatient Period</title>
          <description>The 75% responder rate is defined as the percentage of subjects with a 75 % or greater reduction in focal seizure frequency during the 2-week Inpatient Period compared with the Baseline Period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0679</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.90</ci_lower_limit>
            <ci_upper_limit>19.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change in Weekly Focal Seizure Frequency During the 2-week Inpatient Period</title>
        <description>A negative value in median percent change reflects a reduction from Baseline.</description>
        <time_frame>During the 2-week Inpatient Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change in Weekly Focal Seizure Frequency During the 2-week Inpatient Period</title>
          <description>A negative value in median percent change reflects a reduction from Baseline.</description>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.5" lower_limit="-57.14" upper_limit="41.11"/>
                    <measurement group_id="O2" value="-53.68" lower_limit="-84.61" upper_limit="-22.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change in Weekly Focal Seizure Frequency During the Outpatient Maintenance Period</title>
        <description>A negative value in median percent change reflects a reduction from Baseline.</description>
        <time_frame>During the Outpatient Maintenance Period (8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change in Weekly Focal Seizure Frequency During the Outpatient Maintenance Period</title>
          <description>A negative value in median percent change reflects a reduction from Baseline.</description>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.94" lower_limit="-76.23" upper_limit="-29.09"/>
                    <measurement group_id="O2" value="-26.32" lower_limit="-77.38" upper_limit="-3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Percent Change in Weekly Focal Seizure Frequency During the On-UCB0942 Overall Period</title>
        <description>A negative value in median percent change reflects a reduction from Baseline.</description>
        <time_frame>During the On-UCB0942 Overall Period (approximately 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Percent Change in Weekly Focal Seizure Frequency During the On-UCB0942 Overall Period</title>
          <description>A negative value in median percent change reflects a reduction from Baseline.</description>
          <units>percentage of change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-53.85" lower_limit="-78.01" upper_limit="-34.48"/>
                    <measurement group_id="O2" value="-29.87" lower_limit="-76.39" upper_limit="-11.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure-free Rate (All Seizures) During the 2-week Inpatient Period</title>
        <description>Seizure-free rate is reported as the percentage of seizure-free participants during the 2-week Inpatient Period.</description>
        <time_frame>During the 2-week Inpatient Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure-free Rate (All Seizures) During the 2-week Inpatient Period</title>
          <description>Seizure-free rate is reported as the percentage of seizure-free participants during the 2-week Inpatient Period.</description>
          <units>percentage of particpants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7"/>
                    <measurement group_id="O2" value="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure-free Rate (All Seizures) During the Last 4 Weeks of the Outpatient Maintenance Period</title>
        <description>Seizure-free rate is reported as the percentage of seizure-free participants during the last 4 weeks of the Outpatient Maintenance Period.</description>
        <time_frame>During the last 4 weeks of the Outpatient Maintenance Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure-free Rate (All Seizures) During the Last 4 Weeks of the Outpatient Maintenance Period</title>
          <description>Seizure-free rate is reported as the percentage of seizure-free participants during the last 4 weeks of the Outpatient Maintenance Period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure-free Rate (All Seizures) During the On-UCB0942 Overall Period</title>
        <description>Seizure-free rate is reported as the percentage of seizure-free participants during the On-UCB0942 Overall Period.</description>
        <time_frame>During the On-UCB0942 Overall Period (approximately 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure-free Rate (All Seizures) During the On-UCB0942 Overall Period</title>
          <description>Seizure-free rate is reported as the percentage of seizure-free participants during the On-UCB0942 Overall Period.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>75 % Responder Rate During the Last 4 Weeks of the Outpatient Maintenance Period</title>
        <description>The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.</description>
        <time_frame>During the last 4 weeks of the Outpatient Maintenance Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>75 % Responder Rate During the Last 4 Weeks of the Outpatient Maintenance Period</title>
          <description>The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>75 % Responder Rate During the On-UCB0942 Overall Period</title>
        <description>The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.</description>
        <time_frame>During the On-UCB0942 Overall Period (approximately 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>75 % Responder Rate During the On-UCB0942 Overall Period</title>
          <description>The 75 % responder rate is defined as the percentage of subjects who achieve a 75 % or greater reduction in focal seizure frequency.</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.9"/>
                    <measurement group_id="O2" value="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Seizure Free Days (All Seizures) During the 2-week Inpatient Period</title>
        <description>For the active group, the 2-week Inpatient Period refers to the last 2 weeks of the Inpatient Period, while for the Placebo group, it refers to the first 2 weeks of the Inpatient Period.</description>
        <time_frame>During the 2-week Inpatient Period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seizure Free Days (All Seizures) During the 2-week Inpatient Period</title>
          <description>For the active group, the 2-week Inpatient Period refers to the last 2 weeks of the Inpatient Period, while for the Placebo group, it refers to the first 2 weeks of the Inpatient Period.</description>
          <units>percentage of days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.43" lower_limit="7.14" upper_limit="57.14"/>
                    <measurement group_id="O2" value="57.14" lower_limit="28.57" upper_limit="78.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Seizure-free Days (All Seizures) During the Outpatient Maintenance Period</title>
        <time_frame>During the Outpatient Maintenance Period (8 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (FAS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (FAS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Seizure-free Days (All Seizures) During the Outpatient Maintenance Period</title>
          <units>percentage of days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.79" lower_limit="15.79" upper_limit="80.70"/>
                    <measurement group_id="O2" value="51.35" lower_limit="29.82" upper_limit="69.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study</title>
        <description>Number of subjects experiencing at least one serious adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).</description>
        <time_frame>All study duration (approximately 19 to 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (SS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (SS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reporting at Least One Serious Adverse Event (SAE) During the Course of the Study</title>
          <description>Number of subjects experiencing at least one serious adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subject Withdrawals Due to Adverse Events (AEs) During the Course of the Study</title>
        <description>Number of subjects who withdrew from the study due adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).</description>
        <time_frame>All study duration (approximately 19 to 20 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo/UCB0942 (SS)</title>
            <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
          </group>
          <group group_id="O2">
            <title>UCB0942/UCB0942 (SS)</title>
            <description>Subjects received UCB0942.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subject Withdrawals Due to Adverse Events (AEs) During the Course of the Study</title>
          <description>Number of subjects who withdrew from the study due adverse event (reported by the subject and/or caregiver or observed by the Investigator or inpatient staff).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events were collected from Baseline until Safety Follow Up Visit (up to Week 28).</time_frame>
      <desc>Baseline Characteristics refer to the Safety Set consisting of all subjects in the Randomized Set who received at least 1 dose of Investigational Medicinal Product (IMP). 2 subjects reported multiple Serious Adverse Events (SAEs).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo/UCB0942</title>
          <description>After 2-week in the Inpatient Period, Placebo subjects received the experimental medicine (UCB0942).</description>
        </group>
        <group group_id="E2">
          <title>UCB0942/UCB0942</title>
          <description>Subjects received UCB0942.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Judgement impaired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dysphoria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E2" events="23" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="17" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Muscosloskeletal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" events="24" subjects_affected="17" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="51" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Simple partial seizures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Parasomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB</name_or_title>
      <organization>Cares</organization>
      <phone>+1844599 ext 2273</phone>
      <email>UCBCares@ucb.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

